MDT

81.74

-1.59%↓

VEEV

209.29

-2.32%↓

98.9

-4.01%↓

HQY

76.28

-4.98%↓

PDCO

31.05

+0.49%↑

MDT

81.74

-1.59%↓

VEEV

209.29

-2.32%↓

98.9

-4.01%↓

HQY

76.28

-4.98%↓

PDCO

31.05

+0.49%↑

MDT

81.74

-1.59%↓

VEEV

209.29

-2.32%↓

98.9

-4.01%↓

HQY

76.28

-4.98%↓

PDCO

31.05

+0.49%↑

MDT

81.74

-1.59%↓

VEEV

209.29

-2.32%↓

98.9

-4.01%↓

HQY

76.28

-4.98%↓

PDCO

31.05

+0.49%↑

MDT

81.74

-1.59%↓

VEEV

209.29

-2.32%↓

98.9

-4.01%↓

HQY

76.28

-4.98%↓

PDCO

31.05

+0.49%↑

Home・Aandelen Lijst・BioNTech SE ADR

BioNTech SE ADR

Gesloten

SectorGezondheidszorg

86.32 0.09

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

84.1

Max

90.82

Belangrijke statistieken
By Trading Economics
Inkomsten	143M 301M
Verkoop	-55M 1.2B
EPS	1.08
Winstmarge	25.311
Werknemers	6,772
EBITDA	253M 464M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+58.5% upside

Dividenden
By Dow Jones
Volgende Winsten	5 mei 2025

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-3.3B 23B
Vorige openingsprijs	86.23
Vorige sluitingsprijs	86.32

Nieuwssentiment

By Acuity

67%

33%

346 / 386 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

86.25 / 89.68 Steun & Weerstand

BioNTech SE ADR Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 feb 2025, 18:52 UTC

Belangrijke Marktbewegers

Psychedelic Drug Stocks Up, Vaccine Shares Down After Senate Committee Advances RFK Jr.

15 nov 2024, 10:28 UTC

Belangrijke Marktbewegers

European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department

6 mei 2024, 11:27 UTC

Winsten

BioNTech Swings to Net Loss on Lower Covid Vaccine Sales

15 nov 2024, 11:14 UTC

Marktinformatie

U.S. Vaccine Stocks Fall After Trump Picks Vaccine Skeptic RFK Jr as Health Department Head-- Market Talk

15 nov 2024, 10:34 UTC

Marktinformatie

Vaccine Sector Sell-Off Looks Overdone -- Market Talk

5 aug 2024, 10:02 UTC

Winsten

BioNTech Sees 2024 R&D Expenses EUR2.4B-EUR2.6B >BNTX

5 aug 2024, 10:01 UTC

Winsten

BioNTech Backs 2024 View of Rev EUR2.5B-EUR3.1B >BNTX

5 aug 2024, 10:01 UTC

Winsten

BioNTech: Invested EUR525.6M, or About 90% of 2Q R&D Spend, in Non-Covid-19 Related Activities >BNTX

5 aug 2024, 10:00 UTC

Winsten

BioNTech 2Q-End Cash, Equivalents, Security Investments EUR18.5 Billion >BNTX

5 aug 2024, 09:59 UTC

Winsten

BioNTech 2Q Loss EUR807.8M >BNTX

5 aug 2024, 09:59 UTC

Winsten

BioNTech 2Q Loss/Shr EUR3.36 >BNTX

5 aug 2024, 09:59 UTC

Winsten

BioNTech 2Q Rev EUR128.7M >BNTX

6 mei 2024, 20:15 UTC

Winsten

BioNTech Lifts As Covid Sales Plummet With 90% Of Revenue Still To Come -- IBD

6 mei 2024, 10:47 UTC

Winsten

BioNTech Sees FY24 Rev EUR2.5B-EUR3.1B >BNTX

6 mei 2024, 10:46 UTC

Winsten

Correct: BioNTech 1Q Loss/Shr EUR1.31 >BNTX

6 mei 2024, 10:46 UTC

Winsten

Correct: BioNTech 1Q Loss EUR315.1M >BNTX

6 mei 2024, 10:46 UTC

Winsten

Correct: BioNTech 1Q Rev EUR187.6M >BNTX

6 mei 2024, 10:45 UTC

Winsten

BioNTech 1Q Rev $187.6M >BNTX

6 mei 2024, 10:45 UTC

Winsten

BioNTech 1Q Loss $315.1M >BNTX

6 mei 2024, 10:45 UTC

Winsten

BioNTech 1Q Loss/Shr $1.31 >BNTX

Peer Vergelijking

Prijswijziging

BioNTech SE ADR Prognose

Koersdoel

By TipRanks

58.5% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 139.56 USD 58.5%

Hoogste 171 USD

Laagste 110 USD

Gebaseerd op 17 Wall Street-analisten die 12-maands prijsdoelen bieden voor BioNTech SE ADR - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

17 ratings

Buy

Hold

Sell

Gebaseerd op 17 analisten die aandelenratings hebben gegeven aan BioNTech SE ADR - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

86.25 / 89.68Steun & Weerstand

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

346 / 386 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over BioNTech SE ADR

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac